DK1095140T3 - Neurotrofe faktorer - Google Patents
Neurotrofe faktorerInfo
- Publication number
- DK1095140T3 DK1095140T3 DK99931023.8T DK99931023T DK1095140T3 DK 1095140 T3 DK1095140 T3 DK 1095140T3 DK 99931023 T DK99931023 T DK 99931023T DK 1095140 T3 DK1095140 T3 DK 1095140T3
- Authority
- DK
- Denmark
- Prior art keywords
- neurotrophic factors
- neublastin
- polypeptides
- methods
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/06—Anabolic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA199800904 | 1998-07-06 | ||
US9222998P | 1998-07-09 | 1998-07-09 | |
DKPA199801048 | 1998-08-19 | ||
US9777498P | 1998-08-25 | 1998-08-25 | |
DKPA199801265 | 1998-10-06 | ||
US10390898P | 1998-10-13 | 1998-10-13 | |
US09/347,613 US6593133B1 (en) | 1998-07-06 | 1999-07-02 | Neurotrophic factors |
PCT/DK1999/000384 WO2000001815A2 (en) | 1998-07-06 | 1999-07-05 | Neurotrophic factors |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1095140T3 true DK1095140T3 (da) | 2011-10-31 |
Family
ID=27561795
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK99931023.8T DK1095140T3 (da) | 1998-07-06 | 1999-07-05 | Neurotrofe faktorer |
Country Status (18)
Country | Link |
---|---|
US (6) | US6593133B1 (da) |
EP (2) | EP2290079A3 (da) |
JP (5) | JP2002519061A (da) |
KR (1) | KR100743376B1 (da) |
AT (1) | ATE522609T1 (da) |
AU (1) | AU755114B2 (da) |
CA (1) | CA2336218C (da) |
CY (1) | CY1112101T1 (da) |
DK (1) | DK1095140T3 (da) |
EE (1) | EE05590B1 (da) |
ES (1) | ES2373173T3 (da) |
HU (1) | HU227870B1 (da) |
IS (1) | IS2835B (da) |
NZ (1) | NZ508994A (da) |
PT (1) | PT1095140E (da) |
SI (1) | SI1095140T1 (da) |
TR (1) | TR200100056T2 (da) |
WO (1) | WO2000001815A2 (da) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6593133B1 (en) * | 1998-07-06 | 2003-07-15 | Nsgene A/S | Neurotrophic factors |
US20020055467A1 (en) * | 1998-07-06 | 2002-05-09 | Johansen Teit E. | Novel neurotrophic factors |
CN1243770C (zh) * | 1998-07-14 | 2006-03-01 | 詹森药业有限公司 | 神经营养生长因子 |
US7067473B1 (en) * | 1998-07-14 | 2006-06-27 | Janssen Pharmaceutica N.V. | Neurotrophic growth factor |
US6284540B1 (en) | 1998-09-29 | 2001-09-04 | Washington University | Artemin, a novel neurotrophic factor |
EP1137774A2 (en) * | 1998-12-09 | 2001-10-04 | Amgen Inc. | Grnf4, a gdnf-related neurotrophic factor |
US6943153B1 (en) | 1999-03-15 | 2005-09-13 | The Regents Of The University Of California | Use of recombinant gene delivery vectors for treating or preventing diseases of the eye |
CA2367375A1 (en) * | 1999-03-15 | 2000-09-21 | Chiron Corporation | Use of recombinant gene delivery vectors for treating or preventing diseases of the eye |
EP1820860A3 (en) * | 1999-06-02 | 2008-03-19 | Genentech, Inc. | Methods and compositions for inhibiting neoplastic cell growth |
WO2002051433A2 (en) * | 2000-12-22 | 2002-07-04 | Genentech, Inc. | Use of artemin, a member of the gdnf ligand family for preparing a neuroprotective medicament |
US7442370B2 (en) | 2001-02-01 | 2008-10-28 | Biogen Idec Ma Inc. | Polymer conjugates of mutated neublastin |
CA2436407C (en) * | 2001-02-01 | 2011-08-30 | Biogen, Inc. | Polymer conjugates of neublastin and methods of using same |
US7276580B2 (en) * | 2001-03-12 | 2007-10-02 | Biogen Idec Ma Inc. | Neurotrophic factors |
US20040077543A1 (en) * | 2001-03-28 | 2004-04-22 | Sah Dinah W. Y. | Treatment using neublastin polypeptides |
AU2002250203B2 (en) | 2001-03-28 | 2006-08-10 | Biogen Ma Inc. | Use of neublastin polypeptides for treating neuropathic pain |
WO2004005487A2 (en) * | 2002-07-09 | 2004-01-15 | Bristol-Myers Squibb Company | Polynucleotides encoding a novel testis-specific tubulin tyrosine-ligase-like protein, bgs42 |
JP4571776B2 (ja) * | 2002-11-05 | 2010-10-27 | Jx日鉱日石エネルギー株式会社 | 潤滑油組成物 |
GEP20084464B (en) | 2003-01-31 | 2008-08-25 | Biogen Idec Inc | Mutated neublastin |
ES2479942T3 (es) | 2003-04-18 | 2014-07-25 | Biogen Idec Ma Inc. | Neublastina glucosilada conjugada con polímero |
CN100475846C (zh) | 2003-06-10 | 2009-04-08 | Ns基因公司 | 增加的神经胚素分泌 |
US7598059B2 (en) | 2003-10-02 | 2009-10-06 | Biogen Idec Ma Inc. | Neublastin expression constructs |
CN1897977A (zh) * | 2003-10-20 | 2007-01-17 | Ns基因公司 | 帕金森氏病的体内基因治疗 |
JP4959566B2 (ja) | 2004-08-19 | 2012-06-27 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | トランスホーミング増殖因子βファミリータンパク質の折りたたみ |
PL1786454T3 (pl) * | 2004-08-19 | 2010-12-31 | Biogen Ma Inc | Odmiany neublastyny |
US8138148B2 (en) | 2005-08-16 | 2012-03-20 | Copenhagen University | GDNF derived peptides |
EP1937295A2 (en) * | 2005-10-11 | 2008-07-02 | NS Gene A/S | Treatment of retinopathies using gfr 3 agonists |
TWI501774B (zh) | 2006-02-27 | 2015-10-01 | Biogen Idec Inc | 神經性病症之治療 |
WO2007103182A2 (en) * | 2006-03-01 | 2007-09-13 | Biogen Idec Ma Inc. | Compostions and methods for administering gdnf ligand family proteins |
JP5583005B2 (ja) | 2007-05-01 | 2014-09-03 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | 血管新生を増大させるための組成物および方法 |
WO2009002193A1 (en) * | 2007-06-27 | 2008-12-31 | Auckland Uniservices Limited | Polypeptides and polynucleotides for artemin and related ligands, and methods of use thereof |
WO2009020964A2 (en) * | 2007-08-08 | 2009-02-12 | Biogen Idec Ma Inc. | Anti-neublastin antibodies and uses thereof |
TWI702955B (zh) | 2012-05-15 | 2020-09-01 | 澳大利亞商艾佛蘭屈澳洲私營有限公司 | 使用腺相關病毒(aav)sflt-1治療老年性黃斑部退化(amd) |
US10376562B2 (en) | 2013-03-15 | 2019-08-13 | The Jackson Laboratory | Methods for promoting wound healing and hair growth comprising GDNF administration |
WO2015057736A1 (en) | 2013-10-14 | 2015-04-23 | Indiana University Research And Technology Corporation | Use of acamprosate to modulate erk 1-2 activation in animal models for fxs and asd and individuals diagnosed with fxs and asd |
CN106414474B (zh) | 2014-03-17 | 2021-01-15 | 阿德夫拉姆生物技术股份有限公司 | 用于视锥细胞中增强的基因表达的组合物和方法 |
US20180264081A1 (en) * | 2015-01-18 | 2018-09-20 | Gloriana Therapeutics Sarl | Therapeutic protein formulations |
WO2016141078A1 (en) | 2015-03-02 | 2016-09-09 | Avalanche Biotechnologies, Inc. | Compositions and methods for intravitreal delivery of polynucleotides to retinal cones |
GB2545763A (en) | 2015-12-23 | 2017-06-28 | Adverum Biotechnologies Inc | Mutant viral capsid libraries and related systems and methods |
Family Cites Families (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4352883A (en) | 1979-03-28 | 1982-10-05 | Damon Corporation | Encapsulation of biological material |
US4353888A (en) | 1980-12-23 | 1982-10-12 | Sefton Michael V | Encapsulation of live animal cells |
US4407957A (en) | 1981-03-13 | 1983-10-04 | Damon Corporation | Reversible microencapsulation of a core material |
US5525464A (en) | 1987-04-01 | 1996-06-11 | Hyseq, Inc. | Method of sequencing by hybridization of oligonucleotide probes |
US4883666A (en) | 1987-04-29 | 1989-11-28 | Massachusetts Institute Of Technology | Controlled drug delivery system for treatment of neural disorders |
US5158881A (en) | 1987-11-17 | 1992-10-27 | Brown University Research Foundation | Method and system for encapsulating cells in a tubular extrudate in separate cell compartments |
US5283187A (en) | 1987-11-17 | 1994-02-01 | Brown University Research Foundation | Cell culture-containing tubular capsule produced by co-extrusion |
DE3829766A1 (de) | 1988-09-01 | 1990-03-22 | Akzo Gmbh | Verfahren zur herstellung von membranen |
DE3829752A1 (de) | 1988-09-01 | 1990-03-22 | Akzo Gmbh | Integrale asymmetrische polyaethersulfonmembran, verfahren zur herstellung und verwendung zur ultrafiltration und mikrofiltration |
US5082670A (en) | 1988-12-15 | 1992-01-21 | The Regents Of The University Of California | Method of grafting genetically modified cells to treat defects, disease or damage or the central nervous system |
US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
US5800992A (en) | 1989-06-07 | 1998-09-01 | Fodor; Stephen P.A. | Method of detecting nucleic acids |
US5084350A (en) | 1990-02-16 | 1992-01-28 | The Royal Institution For The Advance Of Learning (Mcgill University) | Method for encapsulating biologically active material including cells |
US5618531A (en) | 1990-10-19 | 1997-04-08 | New York University | Method for increasing the viability of cells which are administered to the brain or spinal cord |
ATE156344T1 (de) | 1991-04-25 | 1997-08-15 | Univ Brown Res Found | Implantierbare, biokompatible immunisolator- trägersubstanz zum abgeben ausgesuchter, therapeutischer produkte |
DK0606217T4 (da) | 1991-06-27 | 2009-03-30 | Bristol Myers Squibb Co | CTL4-receptor, fusionsproteiner indeholdende den samt anvendelse deraf |
KR100246082B1 (ko) | 1991-07-02 | 2000-04-01 | 인헤일, 인코오포레이티드 | 에어로졸화된약제를전달하는방법및장치 |
US5750376A (en) | 1991-07-08 | 1998-05-12 | Neurospheres Holdings Ltd. | In vitro growth and proliferation of genetically modified multipotent neural stem cells and their progeny |
CA2119463C (en) | 1991-09-20 | 2003-09-16 | Leu-Fen H. Lin | Glial cell line-derived neutrophic factor |
US5968502A (en) | 1991-11-05 | 1999-10-19 | Transkaryotic Therapies, Inc. | Protein production and protein delivery |
US5284350A (en) * | 1992-05-22 | 1994-02-08 | Medical Composite Technology | Foldable wheelchair and side frame assembly |
US5785049A (en) | 1994-09-21 | 1998-07-28 | Inhale Therapeutic Systems | Method and apparatus for dispersion of dry powder medicaments |
KR100291620B1 (ko) | 1992-09-29 | 2001-10-24 | 추후제출 | 부갑상선호르몬의활성단편의폐를통한전달방법 |
CA2092271C (en) | 1993-03-09 | 2009-10-13 | Eddie Reed | Use of g-csf for treating taxol side-effects |
DK0802800T3 (da) | 1993-08-12 | 2002-10-07 | Neurotech Sa | Biokompatible immunoisolatoriske kapsler indeholdende genetisk ændrede celler for levering af biologisk aktive molekyler |
DE4339605A1 (de) | 1993-11-20 | 1995-05-24 | Beiersdorf Ag | Desodorierende Wirkstoffkombinationen auf der Basis von alpha, omega-Alkandicarbonsäuren und Fettsäurepartialglyceriden |
US5834029A (en) | 1994-07-20 | 1998-11-10 | Cytotherapeutics, Inc. | Nerve guidance channel containing bioartificial three-dimensional hydrogel extracellular matrix derivatized with cell adhesive peptide fragment |
US5795716A (en) | 1994-10-21 | 1998-08-18 | Chee; Mark S. | Computer-aided visualization and analysis system for sequence evaluation |
US5780014A (en) | 1995-04-14 | 1998-07-14 | Inhale Therapeutic Systems | Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin |
US5654007A (en) | 1995-06-07 | 1997-08-05 | Inhale Therapeutic Systems | Methods and system for processing dispersible fine powders |
US5739307A (en) | 1995-08-28 | 1998-04-14 | Washington University | Polynucleotide encoding neurturin neurotrophic factor |
US5733729A (en) | 1995-09-14 | 1998-03-31 | Affymetrix, Inc. | Computer-aided probability base calling for arrays of nucleic acid probes on chips |
US5641749A (en) * | 1995-11-29 | 1997-06-24 | Amgen Inc. | Method for treating retinal ganglion cell injury using glial cell line-derived neurothrophic factor (GDNF) protein product |
US6299895B1 (en) * | 1997-03-24 | 2001-10-09 | Neurotech S.A. | Device and method for treating ophthalmic diseases |
US6878544B2 (en) * | 1996-04-19 | 2005-04-12 | Neurotech Sa | Retinal cell lines with extended life-span and their applications |
AU732392B2 (en) | 1996-05-08 | 2001-04-26 | Biogen Idec Ma Inc. | Ret ligand (retL) for stimulating neural and renal growth |
US5754524A (en) | 1996-08-30 | 1998-05-19 | Wark; Barry J. | Computerized method and system for analysis of an electrophoresis gel test |
KR100195886B1 (ko) | 1996-11-01 | 1999-06-15 | 김상조 | 당뇨병 치료용 의약조성물 |
WO1998032869A1 (en) | 1997-01-29 | 1998-07-30 | Neurosearch A/S | Expression vectors and methods for in vivo expression of therapeutic polypeptides |
US20020192209A1 (en) * | 1997-09-17 | 2002-12-19 | Genentech, Inc. | Methods and compositions for inhibiting neoplastic cell growth |
US20020055467A1 (en) * | 1998-07-06 | 2002-05-09 | Johansen Teit E. | Novel neurotrophic factors |
US6593133B1 (en) * | 1998-07-06 | 2003-07-15 | Nsgene A/S | Neurotrophic factors |
CN1243770C (zh) | 1998-07-14 | 2006-03-01 | 詹森药业有限公司 | 神经营养生长因子 |
EP1115866A1 (en) * | 1998-09-22 | 2001-07-18 | University of Maryland at Baltimore | Cystine knot growth factor mutants |
US6284540B1 (en) * | 1998-09-29 | 2001-09-04 | Washington University | Artemin, a novel neurotrophic factor |
EP1137774A2 (en) * | 1998-12-09 | 2001-10-04 | Amgen Inc. | Grnf4, a gdnf-related neurotrophic factor |
DK1626058T3 (da) * | 1999-03-08 | 2008-02-25 | Genentech Inc | Sammensætninger og fremgangsmåder til diagnosticering af tumor |
US6361771B1 (en) * | 1999-04-06 | 2002-03-26 | Neurotech S.A. | ARPE-19 as a platform cell line for encapsulated cell-based delivery |
PT1185648E (pt) * | 1999-06-22 | 2007-06-29 | Genentech Inc | Métodos e composições para a inibição do crescimento de células neoplásicas. |
JP2001329126A (ja) | 2000-05-22 | 2001-11-27 | Bridgestone Corp | 硬化性組成物 |
EP1325966B1 (en) * | 2000-09-12 | 2009-04-01 | JFE Steel Corporation | Super-high strength cold-rolled steel sheet and method for production thereof |
US7276580B2 (en) * | 2001-03-12 | 2007-10-02 | Biogen Idec Ma Inc. | Neurotrophic factors |
US20040077543A1 (en) * | 2001-03-28 | 2004-04-22 | Sah Dinah W. Y. | Treatment using neublastin polypeptides |
US7598059B2 (en) * | 2003-10-02 | 2009-10-06 | Biogen Idec Ma Inc. | Neublastin expression constructs |
-
1999
- 1999-07-02 US US09/347,613 patent/US6593133B1/en not_active Expired - Lifetime
- 1999-07-05 EE EEP200100008A patent/EE05590B1/xx not_active IP Right Cessation
- 1999-07-05 EP EP10181304A patent/EP2290079A3/en not_active Withdrawn
- 1999-07-05 PT PT99931023T patent/PT1095140E/pt unknown
- 1999-07-05 TR TR2001/00056T patent/TR200100056T2/xx unknown
- 1999-07-05 SI SI9931062T patent/SI1095140T1/sl unknown
- 1999-07-05 NZ NZ508994A patent/NZ508994A/en not_active IP Right Cessation
- 1999-07-05 AU AU47693/99A patent/AU755114B2/en not_active Ceased
- 1999-07-05 JP JP2000558205A patent/JP2002519061A/ja active Pending
- 1999-07-05 WO PCT/DK1999/000384 patent/WO2000001815A2/en active IP Right Grant
- 1999-07-05 AT AT99931023T patent/ATE522609T1/de active
- 1999-07-05 HU HU0103758A patent/HU227870B1/hu not_active IP Right Cessation
- 1999-07-05 CA CA2336218A patent/CA2336218C/en not_active Expired - Fee Related
- 1999-07-05 EP EP99931023A patent/EP1095140B1/en not_active Expired - Lifetime
- 1999-07-05 KR KR1020017000184A patent/KR100743376B1/ko not_active IP Right Cessation
- 1999-07-05 DK DK99931023.8T patent/DK1095140T3/da active
- 1999-07-05 ES ES99931023T patent/ES2373173T3/es not_active Expired - Lifetime
-
2000
- 2000-09-15 US US09/662,183 patent/US6734284B1/en not_active Expired - Lifetime
- 2000-12-14 IS IS5769A patent/IS2835B/is unknown
-
2004
- 2004-03-22 US US10/806,793 patent/US20040230043A1/en not_active Abandoned
-
2005
- 2005-06-01 JP JP2005161155A patent/JP2005341968A/ja not_active Withdrawn
- 2005-11-10 JP JP2005326745A patent/JP2006122053A/ja not_active Withdrawn
-
2007
- 2007-04-27 JP JP2007120282A patent/JP2007252381A/ja not_active Withdrawn
- 2007-10-31 US US11/932,744 patent/US20080227703A1/en not_active Abandoned
- 2007-11-28 JP JP2007307603A patent/JP2008133282A/ja active Pending
-
2009
- 2009-10-27 US US12/606,602 patent/US20100234293A1/en not_active Abandoned
-
2011
- 2011-04-11 US US13/084,267 patent/US20120252726A1/en not_active Abandoned
- 2011-11-29 CY CY20111101173T patent/CY1112101T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1095140T3 (da) | Neurotrofe faktorer | |
CY1111750T1 (el) | Νευροτροφικοι παραγοντες | |
PT1015585E (pt) | Homologos de ligandos de tie | |
DK1434791T3 (da) | Specifikke bindingsmidler til human angiopoietin-2 | |
ATE411082T1 (de) | Neue verwendung von kurzkettigen carbonsäuren | |
BR0012759A (pt) | Neurotoxinas recombinantes ativáveis | |
ATE407949T1 (de) | Charakterisierung der proteinfamilie von soc/crac kalziumkanälen | |
DK1482040T3 (da) | NL3-TIE-receptortyrosinkinaseligandhomologer | |
DE69839444D1 (de) | Smad 6 und dessen anwendungen | |
SE9602822D0 (sv) | New receptor | |
PE20399A1 (es) | Muteina ob | |
EA200100110A1 (ru) | Нейротрофические факторы | |
SE9604439D0 (sv) | New receptor | |
ATE283358T1 (de) | Protease-ähnliches protein | |
WO2001021794A3 (en) | Smad associating polypeptides |